Bedrijfsoverzicht
Hyperfine, Inc. is a health technology enterprise focused on the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. The company specializes in the Swoop Portable MR Imaging System, which is engineered to generate images at a magnetic field strength lower than that of conventional MRI scanners, addressing specific niche needs in medical imaging. This business operates within the Healthcare sector, specifically the Medical Devices industry, positioning it as a provider of specialized diagnostic equipment rather than general medical supplies. The company's current market capitalization stands at $119.21 million, supported by a trailing twelve-month revenue of $13.56 million and a workforce comprising 102 employees. These valuation and revenue figures indicate that Hyperfine operates as a small-cap entity with a relatively limited revenue base compared to large-cap medical device peers, suggesting a company in a specific growth phase or niche market segment rather than a mature, diversified industry leader.
Financiële gezondheid
Hyperfine, Inc. reported a revenue of $13.56 million over the trailing twelve months, yet recorded a net income of $-35,574,000 and an EBITDA of $-35,995,000. The substantial gap between positive revenue and deeply negative net income reveals a cost structure where expenses, likely driven by research, development, and operational scaling, significantly outpace gross earnings. The company generated free cash flow of $-17,207,124, indicating that while the business generates sales, its cash burn rate is significant and requires external funding or cash reserves to sustain operations. Despite the negative earnings, the company maintains a cash balance of $35.09 million against total debt of $314,000, creating a robust liquidity buffer that mitigates immediate solvency risks. The balance sheet appears conservative regarding leverage, underscored by a debt-to-equity ratio of 0.77, which suggests the company relies more on equity financing than debt obligations. Liquidity management is strong as evidenced by a current ratio of 4.34, meaning the company holds sufficient current assets to cover short-term liabilities more than four times over. Return on equity stands at -79.0% and return on assets at -40.6%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than profits, a common characteristic of high-growth pre-profitability companies.
Waarderingsbeoordeling
The valuation metrics present a complex picture due to the company's unprofitability, with a trailing P/E ratio of N/A and a forward P/E of -3.67. The absence of a trailing P/E and the negative forward P/E imply that the market is pricing in future earnings recovery rather than current profitability, as traditional earnings-based multiples are not applicable. The price-to-book ratio is 2.87, indicating that the market values the company at nearly three times its book value, which suggests a market premium assigned to its intangible assets, proprietary technology, or potential growth options despite current losses. Alternative valuation metrics show a price-to-sales ratio of 8.79 and an EV/EBITDA of -2.33, suggesting that investors are willing to pay a significant multiple of sales for the company, likely betting on future commercialization success of its MRI products. Regarding trading range, the stock has a 52-week high of $2.22 and a 52-week low of $0.53, meaning the current price sits within a wide volatility band that reflects the uncertainty surrounding its profitability trajectory. The beta value of 1.06 indicates that the stock's price volatility is slightly higher than the broader market, moving in tandem with general market fluctuations but with an elevated risk profile typical of small-cap biotech or medical device firms.
Growth & Income
Hyperfine, Inc. demonstrated impressive top-line expansion with a revenue growth rate of 128.0% year-over-year, while earnings growth is N/A due to the company's continued net losses. The disparity between the massive revenue growth and the lack of earnings growth implies that the company is prioritizing rapid market expansion and product adoption over immediate profitability, a strategy typical of companies in the early commercialization phase. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all available resources and cash reserves back into the business to fuel further growth rather than distributing income to shareholders. This reinvestment strategy is necessary given the negative operating margin of -144.9% and profit margin of -262.3%, which highlight the intense capital requirements needed to reach sustainable profitability. The overall growth and income profile is characterized by explosive revenue acceleration funded by existing cash reserves, with no current income generation for investors, reflecting a high-risk, high-reward trajectory dependent on future product success and cost control improvements.